Stoke Therapeutics Inc Cash Flow Conversion Efficiency
Stoke Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Stoke Therapeutics Inc (STOK) has a cash flow conversion efficiency ratio of -0.164x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-56.59 Million) by net assets ($345.55 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Stoke Therapeutics Inc (2017–2025)
Cash flow conversion efficiency of Stoke Therapeutics Inc from 2017 to 2025. This chart illustrates how Stoke Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View STOK stock price for real-time trading data and today's change.
Stoke Therapeutics Inc Cash Flow Conversion Ratio Explained
Stoke Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Stoke Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Stoke Therapeutics Inc ranked by their cash flow conversion efficiency. Also see STOK company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Douglas Emmett Inc
NYSE:DEI
|
0.040x |
|
CHINA CONCH VENT. HD -01
F:68C
|
N/A |
|
Wafer Works
TWO:6182
|
0.005x |
|
Emami Limited
NSE:EMAMILTD
|
0.081x |
|
FirstSun Capital Bancorp Common Stock
NASDAQ:FSUN
|
0.601x |
|
Alembic Pharmaceuticals Limited
NSE:APLLTD
|
0.076x |
|
Suzhou Secote Precision Electronic Co Ltd Class A
SHG:603283
|
0.039x |
|
Beijing Jiuzhou Yi Gui Environmental Technology Co. Ltd.
SHG:688485
|
N/A |
Annual Cash Flow Conversion Efficiency for Stoke Therapeutics Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Stoke Therapeutics Inc from 2017 to 2025. Review STOK free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $352.46 Million | $45.59 Million | 0.129x | +134.10% |
| 2024-12-31 | $229.02 Million | $-86.85 Million | -0.379x | +25.36% |
| 2023-12-31 | $159.56 Million | $-81.07 Million | -0.508x | -194.71% |
| 2022-12-31 | $184.85 Million | $-31.87 Million | -0.172x | +43.89% |
| 2021-12-31 | $217.78 Million | $-66.91 Million | -0.307x | -108.17% |
| 2020-12-31 | $286.08 Million | $-42.22 Million | -0.148x | -6.66% |
| 2019-12-31 | $224.43 Million | $-31.05 Million | -0.138x | -32.60% |
| 2018-12-31 | $105.07 Million | $-10.96 Million | -0.104x | -102.50% |
| 2017-12-31 | $-1.29 Million | $-5.38 Million | 4.167x | -- |
About Stoke Therapeutics Inc
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials fo… Read more